Form 4: iBio CEO Martin Brenner Acquires 230,700 Stock Options
SEC Form 4 Filing
iBio's CEO, Martin Brenner, reports the acquisition of 230,700 stock options in the company.
Summary
- Martin Brenner, CEO and Chief Scientific Officer of iBio, Inc., reported a transaction on February 21, 2025.
- Brenner acquired 230,700 stock options with an exercise price of $3.48.
- These options vest over time, with 25% vesting after one year and the remainder vesting quarterly over the subsequent three years, contingent upon continued employment.
- The options expire on February 20, 2035.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to executive compensation, with a neutral sentiment.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to the CEO may incentivize him to improve the company's performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/21/2025 | Date of stock option grant |
| 02/20/2035 | Expiration date of the stock options |
Keywords
iBio, Martin Brenner, stock options, Form 4, SEC, beneficial ownership, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.